The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Amado et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [22]
In the citing paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
In the citing paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Cited by
Sorted by citations
Items 601–700 of 1,014
Hirashima, Y., Yamada, Y., Tateishi, U., Kato, K., Miyake, M., Horita, Y., Akiyoshi, K., Takashima, A., Okita, N. T., Takahari, D., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26282 · Cited by 67
Su, X. Q., Lacouture, M. E., Jia, Y., & Wu, S. (2009) · Oncology · doi:10.1159/000229752 · Cited by 66
Stricker, T. P., Catenacci, D. V. T., & Seiwert, T. Y. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.013 · Cited by 68
The molecular therapy of colorectal cancer
Waldner, M. J., & Neurath, M. F. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.005 · Cited by 67
KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies
Soulières, D., Greer, W. L., Magliocco, A. M., Huntsman, D. D., Young, S. S., Tsao, M., & Kamel‐Reid, S. (2010) · Current Oncology · doi:10.3747/co.v17is1.614 · Cited by 66
Kim, T. W., Elme, A., Kusić, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Villalobos-Valencia, R., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 67
Agarwal, A., Balić, M., El‐Ashry, D., & Côté, R. J. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000310 · Cited by 72
Wu, X., Li, Y., Chen, X., Huang, Y., He, L., Zhao, K., Huang, X., Zhang, W., Huang, Y., Li, Y., et al. (2020) · Academic Radiology · doi:10.1016/j.acra.2019.12.007 · Cited by 67
Kuo, Y., Chen, J., Fan, C., Li, Y.-S., & Chan, E. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.024 · Cited by 70
Stopfer, L. E., Flower, C. T., Gajadhar, A. S., Patel, B., Gallien, S., López‐Ferrer, D., & White, F. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3804 · Cited by 67
Amann, J. M., Lee, J., Röder, H., Brahmer, J. R., González, A., Schiller, J. H., & Carbone, D. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c8cbd9 · Cited by 66
Dietel, M., Jöhrens, K., von Laffert, M., Hummel, M., Bläker, H., Müller, B. M., Lehmann, A., Denkert, C., Heppner, F. L., Koch, A., et al. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.13 · Cited by 66
Management of stage IV rectal cancer: Palliative options
Ronnekleiv‐Kelly, S. M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i7.835 · Cited by 67
Caja, L., Sancho, P., Bertrán, E., & Fabregat, I. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.041 · Cited by 66
Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
Yang, B., Lum, P., Chen, A., Arends, R., Roskos, L. K., Smith, B. P., & Ruixo, J. J. P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535970-000000000-00000 · Cited by 66
Mekenkamp, L. J., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Börger, M. E., van Vliet, S., Teerenstra, S., Kamping, E. J., Verwiel, E. T. P., Koopman, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-292 · Cited by 69
Blank, P. R., Moch, H., Szucs, T. D., & Schwenkglenks, M. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2267 · Cited by 67
Vilar, E., Mukherjee, B., Kuick, R. D., Raskin, L., Misek, D. E., Taylor, J. M. G., Giordano, T. J., Hanash, S., Fearon, E. R., Rennert, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2432 · Cited by 66
Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Guan, X., & Peeters, M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.010 · Cited by 66
Self-citationChiavarina, B., Nokin, M., Bellier, J., Durieux, F., Blétard, N., Sherer, F., Lovinfosse, P., Peulen, O., Verset, L., Dehon, R., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010213 · Cited by 66
Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions
Yang, Y. P., Peng, J., Sanjun, C., & Ma, Y. (2017) · Journal of Cancer · doi:10.7150/jca.19794 · Cited by 67
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65
Abraham, J. P., Magee, D., Cremolini, C., Antoniotti, C., Halbert, D. D., Xiu, J., Stafford, P., Berry, D. A., Oberley, M. J., Shields, A. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3286 · Cited by 67
El‐Mashtoly, S. F., Yosef, H. K., Petersen, D., Mavarani, L., Maghnouj, A., Hahn, S. A., Kötting, C., & Gerwert, K. B. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01431 · Cited by 65
Jiang, Y., Kimchi, E. T., Staveley-O’Carroll, K. F., Cheng, H., & Ajani, J. A. (2009) · Cancer · doi:10.1002/cncr.24434 · Cited by 66
Weickhardt, A. J., Williams, D. S., Lee, C. K., Chionh, F. J. M., Simes, J. R., Murone, C., Wilson, K., Parry, M. M., Asadi, K., Scott, A. M., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.209 · Cited by 66
Maßmann, A., Rodt, T., Marquardt, S., Seidel, R., Thomas, K., Wacker, F. K., Richter, G. M., Kauczor, H., Bücker, A., Pereira, P. L., et al. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1308-9 · Cited by 67
Predictive and Prognostic Markers in Colorectal Cancer
George, B., & Kopetz, S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0162-3 · Cited by 66
Vijayaraghavan, A., Efrusy, M. B., Göke, B., Kirchner, T., Santas, C. C., & Goldberg, R. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.26400 · Cited by 64
Peeters, M., Price, T. J., & Laethem, J. V. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0167 · Cited by 64
Self-citationAberrant signaling pathways in pancreatic cancer: A two compartment view
McCleary‐Wheeler, A. L., McWilliams, R. R., & Fernández-Zapico, M. E. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20827 · Cited by 69
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64
Reidy‐Lagunes, D. L., Vakiani, E., Segal, M. F., Hollywood, E. M., Tang, L. H., Solit, D. B., Pietanza, M. C., Capanu, M., & Saltz, L. B. (2012) · Cancer · doi:10.1002/cncr.27459 · Cited by 64
Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3140 · Cited by 64
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 64
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
Molecular therapy of colorectal cancer: Progress and future directions
Weng, W., Feng, J., Qin, H., & Ma, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28722 · Cited by 63
Hawes, D., Shi, S., Dabbs, D. J., Taylor, C. R., & Côté, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3966-2.00016-3 · Cited by 64
Cenaj, O., Ligon, A. H., Hornick, J. L., & Sholl, L. M. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz031 · Cited by 64
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 64
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 69
Igarashi, H., Kurihara, H., Mitsuhashi, K., Ito, M., Okuda, H., Kanno, S., Naito, T., Yoshii, S., Takahashi, H., Kusumi, T., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4264-7 · Cited by 63
Yoshino, T., Muro, K., Yamaguchi, K., Nishina, T., Denda, T., Kudo, T., Okamoto, W., Taniguchi, H., Akagi, K., Kajiwara, T., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.007 · Cited by 62
Amankwatia, E. B., Chakravarty, P., Carey, F. A., Weidlich, S., Steele, R. J., Munro, A. J., Wolf, C. R., & Smith, G. C. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.125 · Cited by 63
Fiorentino, M., Altimari, A., Maglio, G. D., Gruppioni, E., Capizzi, E., de Biase, D., Degiovanni, A., D’Errico, A., Pession, A., Pizzolitto, S., et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s42369 · Cited by 63
Morgan, S. R., Whiteley, J. L., Donald, E. L., Smith, J. C., Eisenberg, M. T., Kallam, E., & Kam-Morgan, L. N. W. (2012) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s8798 · Cited by 63
Molecular predictive and prognostic markers in colon cancer
Winder, T., & Lenz, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.005 · Cited by 64
Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Boeckx, C., de Beeck, K. O., Wouters, A., Deschoolmeester, V., Limame, R., Zwaenepoel, K., Specenier, P. M., Pauwels, P., Vermorken, J. B., Peeters, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.039 · Cited by 64
Self-citationFrom Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A. C., Leong, S., Diamond, J. R., & Eckhardt, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 64
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors
Gilbert, J. A., Adhikari, L., Lloyd, R. V., Rubin, J., Haluska, P., Carboni, J. M., Gottardis, M. M., & Ames, M. M. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0318 · Cited by 65
18F-FDG PET/CT imaging in rectal cancer: relationship with theRASmutational status
Lovinfosse, P., Koopmansch, B., Lambert, F., Jodogne, S., Kustermans, G., Hatt, M., Visvikis, D., Seidel, L., Polus, M., Albert, A., et al. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160212 · Cited by 63
Passot, G., Denbo, J. W., Yamashita, S., Kopetz, S., Chun, Y. S., Maru, D. M., Overman, M. J., Brudvik, K. W., Conrad, C. H., Aloia, T. A., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.07.032 · Cited by 63
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Yu, X., Marshall, M. J. E., Cragg, M. S., & Crispin, M. (2017) · BioDrugs · doi:10.1007/s40259-017-0223-8 · Cited by 65
Santoro, V., Jia, R., Thompson, H., Nijhuis, A. M., Jeffery, R. E., Kiakos, K., Silver, A. R., Hartley, J. A., & Hochhauser, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv394 · Cited by 61
Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review
Lampejo, T., Kavanagh, D. O., Clark, J., Goldin, R. D., Osborn, M., Ziprin, P., & Cleator, S. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605984 · Cited by 62
Malapelle, U., Bellevicine, C., Zeppa, P., Palombini, L., & Troncone, G. (2010) · Diagnostic Cytopathology · doi:10.1002/dc.21512 · Cited by 64
Mita, H., Toyota, M., Aoki, F., Akashi, H., Maruyama, R., Sasaki, Y., Suzuki, H., Idogawa, M., Kashima, L., Yanagihara, K., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-198 · Cited by 62
Bartley, A. N., Hamilton, S. R., Alsabeh, R., Ambinder, E. P., Berman, M. A., Collins, E., Fitzgibbons, P. L., Gress, D. M., Nowak, J. A., Samowitz, W. S., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0231-cp · Cited by 63
KRASandBRAFgene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
Ye, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i5.1595 · Cited by 68
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 62
Chung, C. H., Seeley, E. H., Röder, H., Grigorieva, J., Tsypin, M., Roder, J., Burtness, B. A., Argiris, A. E., Forastiere, A. A., Gilbert, J., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0937 · Cited by 60
Zhang, Y., Li, C., Zhou, Y., & Lu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.2840 · Cited by 61
Molecular markers for colon diagnosis, prognosis and targeted therapy
Herzig, D. O., & Tsikitis, V. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23806 · Cited by 63
Colorectal cancer in review: the role of the EGFR pathway
Saif, M. W. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003593962 · Cited by 61
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
Umeda, Y., Nagasaka, T., Mori, Y., Sadamori, H., Sun, D., Shinoura, S., Yoshida, R., Satoh, D., Nobuoka, D., Utsumi, M., et al. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0531-9 · Cited by 61
Cost implications of new treatments for advanced colorectal cancer
Wong, Y., Meropol, N. J., Speier, W. F., Sargent, D. J., Goldberg, R. M., & Beck, J. R. (2009) · Cancer · doi:10.1002/cncr.24246 · Cited by 61
Shetty, S. J., Thomas, P., Ramanan, B., Sharma, P., Govindarajan, V., & Loggie, B. W. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.10.053 · Cited by 61
Prognostic Role of KRAS, NRAS, BRAF and PIK3CA Mutations in Advanced Colorectal Cancer
Foltran, L., Maglio, G. D., Pella, N., Ermacora, P., Aprile, G., Masiero, E., Giovannoni, M., Iaiza, E., Cardellino, G. G., Lutrino, S. E., et al. (2015) · Future Oncology · doi:10.2217/fon.14.279 · Cited by 61
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 61
Lee, S.-K., Hwang, J.-H., & Choi, K.-Y. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.01.001 · Cited by 61
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 60
Hecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 63
Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
Asghar, U. S., Hawkes, E. A., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.040 · Cited by 61
Esophagogastric cancer: Targeted agents
Ku, G. Y., & Ilson, D. H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.009 · Cited by 59
Karkera, J. D., Cardona, G. M., Bell, K., Gaffney, D. S., Portale, J. C., Santiago-Walker, A., Moy, C. H., King, P., Sharp, M. C., Bahleda, R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0518 · Cited by 60
Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
Pfohl, U., Pflaume, A., Regenbrecht, M., Finkler, S., Adelmann, Q. G., Reinhard, C., Regenbrecht, C. R. A., & Wedeken, L. (2021) · Cells · doi:10.3390/cells10040928 · Cited by 68
Huang, C.-W., Tsai, H., Chen, Y., Huang, C., Ma, C., Lu, C., Kuo, C., Wu, D., Chai, C., & Wang, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-599 · Cited by 60
Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N. K., Makrantonakis, P., Xynogalos, S., Christophyllakis, C., Kouroussis, C., Vamvakas, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.594 · Cited by 60
Saridaki, Z., Weidhaas, J. B., Lenz, H., Laurent‐Puig, P., Jacobs, B., Schutter, J. D., Roock, W. D., Salzman, D. W., Zhang, W., Yang, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0348 · Cited by 61
Bebb, G. D., Smith, C. J., Rorke, S., Boland, W. K., Nicacio, L., Sukhoo, R., & Brade, A. M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1379-9 · Cited by 60
Chemotherapy for Colorectal Cancer Liver Metastases
Alberts, S. R., & Wagman, L. D. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0142 · Cited by 60
Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer
Azuara, D., Morell, M., Gausachs, M., Rodríguez‐Moranta, F., Fabregat, J., Busquets, J., Peláez, N., Boadas, J., Galter, S., Moreno, V. R., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.186577 · Cited by 60
Patient subgroup identification for clinical drug development
Huang, X., Sun, Y., Trow, P. B., Chatterjee, S., Chakravartty, A., Tian, L., & Devanarayan, V. (2017) · Statistics in Medicine · doi:10.1002/sim.7236 · Cited by 60
Bennett, L., Zhao, Z., Barber, B. R., Zhou, X., Peeters, M., Zhang, J., Xu, F., Wiezorek, J. S., & Douillard, J.-Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.409 · Cited by 59
Self-citationWatanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Ikeuchi, H., & Eshima, K. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.029 · Cited by 61
Muro, K., Yoshino, T., Doi, T., Shirao, K., Takiuchi, H., Hamamoto, Y., Watanabe, H., Yang, B.-B., & Asahi, D. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp016 · Cited by 59
Nayak, T. K., Garmestani, K., Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071290 · Cited by 59
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Sánchez‐Muñoz, A., Gallego, E., de Luque, V., Perez‐Rivas, L. G., Vicioso, L., Ribelles, N., Lozano, J., & Alba, E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-136 · Cited by 59
Fernández, I. F., Blanco, S., Lozano, J., & Lazo, P. A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01581-09 · Cited by 57
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Morgan, M. A., Parsels, L. A., Maybaum, J., & Lawrence, T. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1032 · Cited by 59
Computational pathology: Exploring the spatial dimension of tumor ecology
Nawaz, S., & Yuan, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.018 · Cited by 62
Segelov, E., Thavaneswaran, S., Waring, P. M., Desai, J., Robledo, K. P., Gebski, V., Élez, E., Nott, L. M., Karapetis, C. S., Lunke, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6843 · Cited by 59
Rosa, M. D., Rega, D., Costabile, V., Duraturo, F., Niglio, A., Izzo, P., Pace, U., & Delrio, P. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16659790 · Cited by 61
Gong, J., Cho, M. T., Sy, M., Salgia, R., & Fakih, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15030 · Cited by 117
Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063358 · Cited by 60
Molecular Diagnostics of Colorectal Cancer
Bedeir, A., & Krasinskas, A. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0613-rair.1 · Cited by 59
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Palacín-Aliana, I., Garcia‐Romero, N., Asensi-Puig, A., Carrión-Navarro, J., González‐Rumayor, V., & Ayuso‐Sacido, Á. (2021) · Biomedicines · doi:10.3390/biomedicines9080906 · Cited by 63
Lin, Y., Paolucci, I., Brock, K. K., & Odisio, B. C. (2021) · Cancers · doi:10.3390/cancers13163926 · Cited by 60
Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer
Kawada, K., Toda, K., Nakamoto, Y., Iwamoto, M., Hatano, E., Chen, F., Hasegawa, S., Togashi, K., Date, H., Üemoto, S., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160614 · Cited by 58
Metadata
- Authors
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
- Affiliations
- Ghent University Hospital (BE)
- Amgen (United States) (US)
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1626-1634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106789440
- Cited by
- 3,207
- References
- 38
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
- FWCI
- 169.59
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-06-14)
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
- MeSH terms
- Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
